Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Shi, Sheng Bin ^a   Hu, Rong Hang ^b   Qi, Jie Lin ^a   Tang, Xiao Yong ^a   Tian, Jing ^a   Li, Rui ^a   Chang, Chun Xiao ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b JINING MEDICAL UNIVERSITY   (China)

Author keywords

Erlotinib as second line treatment; Lung adenocarcinoma; Oxaliplatin; Pemetrexed

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; ERLOTINIB; FOLIC ACID; OXALIPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84875877496     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0550-7     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-25.
3. Ozkaya S, Findik S, Atici AG, et al. Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non- small cell lung cancer patients. Neoplasma. 2011;58(4):348-51.
4. Ramalingam S, Belani C. Systemic chemotherapy for advanced nonsmall cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Suppl 1):5-13.
5. Fiala O, Pesek M, Finek J, et al. Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy. Neoplasma. 2013;60(2):129-34.
6. Qi WX, Shen Z, Lin F, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(10):5177-82.
7. Crvenkova S, Ivkovski Lj, Dimovski A, et al. Effectiveness of Erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience. Prilozi. 2012;33(1):303-11.
8. Gridelli C, Brodowicz T, Langer CJ, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2012;13(5):340-6.
9. Weinstein JN, Myers TG, O'Connor PM, et al. An information intensive approach to the molecular pharmacology of cancer. Science. 1997;275:343-9.
10. Bidoli P, Zilembo N, Cortinovis D, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian trials in medical oncology study. Ann Oncol. 2007;18:461-7.
11. Weissman CH, Reynolds CH, Neubauer MA, et al. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced nonsmall cell lung cancer. J Thorac Oncol. 2011;6:358-64.
12. Weissman CH, Reynolds CH, Neubauer MA, et al. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(2):358-64.
13. Mir O, Boudou-Rouquette P, Giroux J, et al. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer. 2012;77(1):104-9.
14. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2004;15(7):1123-9.
15. Raez LE, Kobina S, Santos ES. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11(1):18-24.
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. Cancer J Clin. 2005;55(1):10-30.
17. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007;18(2):317-23.
18. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-63.
19. Stordal B, Pavlakis N, Davey R. Oxaliplatin for treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev. 2007;33(4):347-57.
20. Heist RS, Fidias P, Huberman M, et al. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(10):1153-8.
21. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with Oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11:690-6.
22. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010;28(4):614-9.
23. Yang CH, Simms L, Park K, et al. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol. 2010;5:688-95.